Nintedanib Arrow

Nintedanib, the active ingredient in Nintedanib Arrow, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer when given with docetaxel. GNH USA supplies Nintedanib Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib is indicated for fibrotic lung disorders and selected oncology regimens. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination with docetaxel): improves overall survival and progression‑free survival.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Decreased appetite - Elevated liver enzymes - Abdominal pain

Serious or Rare Side Effects: - Hepatic failure or severe liver injury - Major bleeding events - Gastrointestinal perforation - Severe hypertension or arterial thromboembolism - Interstitial lung disease exacerbation

Before initiating therapy, clinicians should consider several safety measures. - Monitor liver function: obtain baseline and periodic hepatic enzyme tests. - Assess bleeding risk: avoid in patients with active hemorrhage or uncontrolled anticoagulation. - Evaluate cardiovascular status: monitor blood pressure regularly during treatment. - Contraindicated in severe hepatic impairment: do not use in patients with Child‑Pugh C liver disease. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Nintedanib can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - P‑glycoprotein inhibitors (e.g., itraconazole): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may lower drug levels and effectiveness. - Antiplatelet agents (e.g., aspirin): monitor for signs of bleeding. - Diuretics: watch for dehydration and renal function changes.